Show simple item record

dc.contributor.authorMuley, Helena
dc.contributor.authorValencia, Karmele
dc.contributor.authorCasas, Josefina
dc.contributor.authorMoreno, Bea
dc.contributor.authorBotella, Luis
dc.contributor.authorLecanda, Fernando
dc.contributor.authorFadó, Rut
dc.contributor.authorCasals, Núria
dc.date.accessioned2023-02-03T15:38:52Z
dc.date.available2023-02-03T15:38:52Z
dc.date.issued2023
dc.identifier.citationMuley, Helena; Valencia, Karmele; Casas, Josefina [et al.]. Cpt1c downregulation causes plasma membrane remodelling and anthracycline resistance in breast cancer. International Journal of Molecular Sciences, 2023, 24(2), 946. Disponible en: <https://www.mdpi.com/1422-0067/24/2/946>. Fecha de acceso: 3 feb. 2023. DOI: 10.3390/ijms24020946ca
dc.identifier.issn1422-0067ca
dc.identifier.urihttp://hdl.handle.net/20.500.12328/3548
dc.description.abstractBreast cancer (BC) is the most common malignancy in women worldwide. While the main systemic treatment option is anthracycline-containing chemotherapy, chemoresistance continues to be an obstacle to patient survival. Carnitine palmitoyltransferase 1C (CPT1C) has been described as a poor-prognosis marker for several tumour types, as it favours tumour growth and hinders cells from entering senescence. At the molecular level, CPT1C has been associated with lipid metabolism regulation and important lipidome changes. Since plasma membrane (PM) rigidity has been associated with reduced drug uptake, we explored whether CPT1C expression could be involved in PM remodelling and drug chemoresistance. Liquid chromatography-high resolution mass spectrometry (LC-HRMS) lipid analysis of PM-enriched fractions of MDA-MB-231 BC cells showed that CPT1C silencing increased PM phospholipid saturation, suggesting a rise in PM rigidity. Moreover, CPT1C silencing increased cell survival against doxorubicin (DOX) treatment in different BC cells due to reduced drug uptake. These findings, further complemented by ROC plotter analysis correlating lower CPT1C expression with a lower pathological complete response to anthracyclines in patients with more aggressive types of BC, suggest CPT1C as a novel predictive biomarker for BC chemotherapy.en
dc.format.extent18ca
dc.language.isoengca
dc.publisherMDPIca
dc.relation.ispartofInternational Journal of Molecular Sciencesca
dc.relation.ispartofseries24
dc.relation.urihttps://www.mdpi.com/1422-0067/24/2/946ca
dc.rights© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.otherCPT1Cca
dc.subject.otherQuimioresistènciaca
dc.subject.otherAbsorció de fàrmacsca
dc.subject.otherCàncer de pulmóca
dc.subject.otherDoxorubicinaca
dc.subject.otherMembrana plasmàticaca
dc.subject.otherRemodelació de lípidsca
dc.subject.otherSaturació d'àcids grassosca
dc.subject.otherCPT1Ces
dc.subject.otherQuimiorresistenciaes
dc.subject.otherConsumo de drogases
dc.subject.otherCáncer de mamaes
dc.subject.otherDoxorrubicinaes
dc.subject.otherMembrana de plasmaes
dc.subject.otherRemodelación de lípidoses
dc.subject.otherSaturación de ácidos grasoses
dc.subject.otherCPT1Cen
dc.subject.otherChemoresistanceen
dc.subject.otherDrug uptakeen
dc.subject.otherBreast canceren
dc.subject.otherDoxorubicinen
dc.subject.otherPlasma membraneen
dc.subject.otherLipid remodellingen
dc.subject.otherFatty acid saturationen
dc.titleCpt1c downregulation causes plasma membrane remodelling and anthracycline resistance in breast canceren
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc61ca
dc.subject.udc616ca
dc.identifier.doihttps://dx.doi.org/10.3390/ijms24020946ca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/
Share on TwitterShare on LinkedinShare on FacebookShare on TelegramShare on WhatsappPrint